Main Article Content
Abstract
Background
COPD is predicted to be the third most common cause of death and chronic disability in the world by 2020. The term COPD encompasses several conditions. These include airflow obstruction with little reversibility, chronic bronchitis, emphysema, and small airways disease. Outcomes when hospitalized are poor, with 34% being re-admitted and 14% dying within 3 months.
Aims and objectives
To monitor, evaluate and compare the adverse effect profile of Ofloxacin and Ciprofloxacin in acute exacerbation of chronic bronchitis.
Methods
This was a prospective, observational study done in 200 patients of clinically diagnosed acute bronchitis in the department of pulmonology, SMC/GGH, Vijayawada. Newly diagnosed 200patients of acute bronchitis (from January 2017 to June 2017), pulmonology outpatient department, GGH, SMC, VJA of age 18–65 years of either gender who were prescribed either Levofloxacin (n = 100) or ofloxacin (OZP group, n = 100) and who gave written informed consent were enrolled. One group of the patients received Tab. Ofloxacin 400 mg BD and other group received Tab. Levofloxacin 500 mg OD for 7 days. The study duration was 6 months.
Results
In Ofloxacin group 63 patients reported ADRs out of which 40 are male and 23 are female. In Levofloxacin group, 19 patients reported ADR, of which 10 were men and 09 women (figure 1). Out of 63 ADRs in ofloxacin group 50 patients reported ADRs associated with CNS, 11patients reported ADRs associated with GIT & 02were associated with skin and its appendages. Out of 19 ADRs in levofloxacin group 10 patients reported ADRs associated with CNS, 08 patients reported ADRs associated with GIT & 01were associated with skin and its appendages (figure 2).
Conclusion
Even though, fluoroquinolones have excellent efficacy profile there are concerns about their safety. The present study concluded that no serious ADRs noted in both groups. But ofloxacin group of patients have shown increased incidence of ADRs associated with CNS especially Insomnia.
Keywords
Article Details
References
- [1]. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2012, 2095–2128
- [2]. Roberts CM, Lowe D, Bucknell CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax. 57, 2002, 137–41
- [3]. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis. 35, 2002, 1505–1511.
- [4]. Halkin H. Adverse effects of the fluoroquinolones. RevInfect Dis. 10, 1988, S258–S261
- [5]. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem. 8, 2001, 371–384
- [6]. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28, 1999, 352–64.
References
[1]. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2012, 2095–2128
[2]. Roberts CM, Lowe D, Bucknell CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax. 57, 2002, 137–41
[3]. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis. 35, 2002, 1505–1511.
[4]. Halkin H. Adverse effects of the fluoroquinolones. RevInfect Dis. 10, 1988, S258–S261
[5]. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem. 8, 2001, 371–384
[6]. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28, 1999, 352–64.